Key Drivers
- Cash Cushion
- Profit Slump
- Low Leverage
AIAI Summary
BIO is no longer a simple quality-compounder story; the key issue now is that its strong net cash position buys time, but a sharp quarterly earnings breakdown and weak academic end-market demand mean investors should treat the stock as a credibility and demand-visibility problem until management proves operating leverage can recover.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Profit Slump
- •Low Leverage
BIO remains financially resilient with strong liquidity, low leverage, and positive cash flow, but the latest quarter showed a severe profitability collapse despite steady gross margins.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Low-240s support
- •Mid-250s resistance
BIO has remained in a clear downtrend over the last month, but the recent bounce from the low-$240s suggests short-term stabilization, with the mid-$250s and then $280 as the key levels to reclaim.
Sharp drop from the high-$290s to $247.53, followed by a weak rebound off the low-$240s
Sentiment & News
Key News Insights:
- •NIAID Funding
- •Earnings Miss
- •Listing Pressure
Valion Bio stood out with major NIAID funding support, while Bio-Rad faced earnings pressure and BIO-key dealt with Nasdaq compliance and trading suspension, underscoring a mixed-to-negative sector backdrop.
The news is likely supportive for Valion Bio but negative for Bio-Rad and especially BIO-key, which faces heightened investor and listing risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings